Efficacy of a biological response modifier in preventing Staphylococcus aureus intramammary infections after calving.
A change in the epidemiology of mastitis in recent years has emphasized the role of the udder immune system in the pathogenesis of Staphylococcus aureus. Therefore, if the bovine or udder immune capability could be enhanced, susceptibility to Staph. aureus could be reduced and antibiotic efficacy could be increased. Immune system defense mechanisms could be enhanced by vaccination and by biological response modifiers. Within this latter group, a biological response modifier obtained from Parapox ovis that was attenuated over 200 tissue culture passages was recently developed and commercialized in some European countries. This study reports the results of a field trial on the efficacy of this biological response modifier in reducing Staph. aureus intramammary infection (IMI) after calving in primiparous and pluriparous cows. The trial included 106 cows sampled six times (55 cows from herd A and 51 from herd B) for a total of 2544 quarter milk samples. The analysis of IMI prevalence showed that 25.09% of samples were bacteriologically positive in the placebo group, and 23.17% of the positive samples were observed in the biological response modifier group. Staphylococcus aureus IMI had a frequency of 11.44% in the placebo group and 6.00% in the biological response modifier group. The dynamic of the hazards showed significantly lower rates in the biological response modifier group than in the placebo group (risk ratio = 0.47). Treatment with the parapox-containing biological response modifier showed significant reduction of Staph. aureus IMI around calving, and this reduction was attributed to an increase in immune defenses.
Zecconi
A
A
Istituto Malattie Infettive Profilassi e Polizia Veterinaria Università degli Studi di Milano, Italy.
Bronzo
V
V
Casula
A
A
Luzzago
C
C
Moroni
P
P
Piccinini
R
R
Spreafico
G
G
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002417:Cattle; D005260:Female; D007155:Immunologic Factors / Q000627:therapeutic use*; D008414:Mastitis, Bovine / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*; D018157:Parapoxvirus / Q000276:immunology; D013203:Staphylococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; C076692:Baypamun HK; D007155:Immunologic Factors; D014765:Viral Vaccines